Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

Li OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comerscritical
-/- inconclusive
    Meng OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comerscritical
    		17/25 inconclusive
      Yang OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comersserious
      		43/83 inconclusive
        Zhang OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comersserious
        		188/940 suggested
        • suggested 63 % decrease in deaths but with a low degree of certainty due to high risk of bias
        Bean OBSRenin-angiotensin-system-acting agentscontrolCOVID 19 all comersserious
        		37/168 suggested
        • suggested 71 % decrease in death or transfer to ICU but with a low degree of certainty due to high risk of bias
        Yan et al. OBSangiotensin converting enzyme inhibitors (ACEIs)controlCOVID 19 all comerscritical
        		-/- inconclusive
          Yan et al. OBSangiotensin receptor blockers (ARBs)controlCOVID 19 all comerscritical
          		-/- inconclusive

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

             

            - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons